AstraZeneca Faces Call For Sanctions

Law360, New York (July 5, 2007, 12:00 AM EDT) -- Drug maker AstraZeneca wants to derail discovery in the case over antipyschotic Seroquel, creating a “discovery filibuster,” according to plaintiffs in the multidistrict litigation.

In their briefs filed Tuesday opposing AstraZeneca's motion to implement case-specific discovery and calling for sanctions, plaintiffs argue the pharmaceutical company's plan is “anything but efficient, cost effective or fair.”

The product liability action, in which plaintiffs allege a link between Seroquel and organ damage, has been mired in disputes over information disclosure for several months.

AstraZeneca had asked a Florida district...
To view the full article, register now.